Reven Housing REIT, Inc. (NASDAQ:RVEN)

Reven Housing REIT, Inc. is engaged in the acquisition and ownership of portfolios of single family rental properties. It owns and operates primarily in Florida, Georgia, Mississippi, Tennessee, Texas and the United States. Reven Housing REIT, Inc. is headquartered in La Jolla, California.

Reven Housing REIT, Inc. (NASDAQ:RVEN)’s Financial Overview

Reven Housing REIT, Inc. (NASDAQ) surged 17.85% yesterday to close its trading session at $3.5. Reven Housing REIT, Inc. has 52-Week high of $4.9 and 52-Week Low of $2.32. The stock touched its 52-Week High on 4.90 and 52-Week Low on 2.32. The stock traded with the volume of 5257 shares yesterday. The firm shows the market capitalization of $45.36 Million.

The firm is trading with SMA20 of -8.7 Percent, SMA50 of -11.97 Percent and SMA200 of -10.76 percent. Reven Housing REIT, Inc. has P/S value of 5.27 while its P/B value stands at 1.2. Similarly, the company has Return on Assets of -3.3 percent, Return on Equity of -7.1 percent and Return on Investment of -1 Percent. The company shows Gross Margin and Operating Margin of 53 percent and -0.6 percent respectively.

The Stock currently has Analyst’ mean Recommendation of 0 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.

There is no forecast data available.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

Benitec Biopharma Limited (NASDAQ:BNTC)

Benitec Biopharma Limited is a biotechnology company which developed a patented gene silencing technology delivered by gene therapy called DNA directed RNA interference. The company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including hepatitis C and B, drug resistant lung cancer and wet age-related macular degeneration. Benitec Biopharma Limited is based in Sydney, Australia.

Benitec Biopharma Limited (NASDAQ:BNTC)’s Financial Outlook

The 1 analysts offering 12-month price forecasts for Benitec Biopharma Ltd have a median target of 5.14, with a high estimate of 5.14 and a low estimate of 5.14. The median estimate represents a +155.55% increase from the last price of 2.01.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

The Stock declined -2.42% and closed its last trading session at $2.01. The company has the market capitalization of $516.63 Million. The stock has 52-week high of $4.9 and 52-Week low of $1.85. The firm touched its 52-Week high on 4.90 and 52-Week low on 1.85. The company has volume of 7008 shares. The company has a total of 257.03 Million shares outstanding.

The company has YTD performance of -32.02 percent. Beta for Benitec Biopharma Limited stands at 0 while its ATR (average true range) is 0.18. The company has Weekly Volatility of 5.35%% and Monthly Volatility of 7.27%%.

Benitec Biopharma Limited has distance from 20-day Simple Moving Average (SMA20) of -11.49%, Distance from 50-Day Simple Moving Average of -15.22 percent and Distance from 200-Day Simple Moving Average of -25.22%.

The Company currently has ROA (Return on Assets) of 0 percent, Return on Equity (ROE) of 0 Percent and Return on Investment (ROI) of 0% with Gross margin of 0 percent and Operating & Profit margin of 0% and 0% respectively.



Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *